What's in Algemeen Ziekenhuis Maria Middelares's pipeline?

Algemeen Ziekenhuis Maria Middelares has 5 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Algemeen Ziekenhuis Maria Middelares's portfolio?

Top competitors by shared drug class: Fundación Santa Fe de Bogota, University Hospital, Bordeaux.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/algemeen-ziekenhuis-maria-middelares.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Algemeen Ziekenhuis Maria Middelares — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Algemeen Ziekenhuis Maria Middelares pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Norepinephrine (dynamic group)	Norepinephrine (dynamic group)	marketed	Catecholamine vasopressor	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor	Cardiovascular
Levobupivacaine Hydrochloride 0.25 % Injectable Solution	Levobupivacaine Hydrochloride 0.25 % Injectable Solution	marketed
Plasma-lyte (static group)	Plasma-lyte (static group)	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution		Critical Care / Fluid and Electrolyte Management
Plasma-lyte (dynamic group)	Plasma-lyte (dynamic group)	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution		Critical Care / Fluid and Electrolyte Management
Norepinephrine (static group)	Norepinephrine (static group)	marketed	Catecholamine vasopressor	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor	Cardiovascular

Therapeutic area mix

Cardiovascular · 2
Critical Care / Fluid and Electrolyte Management · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Fundación Santa Fe de Bogota · 1 shared drug class
University Hospital, Bordeaux · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Algemeen Ziekenhuis Maria Middelares:

Cite this brief

Drug Landscape (2026). Algemeen Ziekenhuis Maria Middelares — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/algemeen-ziekenhuis-maria-middelares. Accessed 2026-05-17.